Home / Transcripts / Coherus Oncology, Inc. (CHRS) · May 11, 2026

Coherus Oncology, Inc. (CHRS) Earnings Call Transcript

May 11, 2026

NASDAQ US Health Care Biotechnology earnings 49 min

Earnings Call Speaker Segments

Carrie Graham executive
#1

Thanks, Heidi. Good afternoon, everyone, and welcome to the First Quarter 2026 Earnings Conference Call for Coherus Oncology. Here with me today to go over our results are Denny Lanfear, our Chief Executive Officer at Coherus; Dr. Rosh Dias, who serves as Chief Medical Officer; Dr. Theresa Lavallee, our Chief Scientific and Development Officer; Sameer Goregaoker, Chief Commercial Officer; and Bryan McMichael, Chief Financial Officer. Before we begin, please let me note that forward-looking statements about Coherus' current expectations for future events are part of today's call. Results in reality could differ materially, and we have no obligation to update or revise any forward-looking statements. For additional details about risks and uncertainties, please refer to the press release we issued today as well as our quarterly report on Form 10-Q. I'll now hand the call over to Denny.

Dennis Lanfear executive
#2

Okay, thanks Carrie, and I appreciate everyone being with us this afternoon for the Q1 2026 quarterly call. To begin, I want to walk through the company's strategy quickly so that we're all on the same page, our new investors included. At the heart of that strategy sits LOQTORZI, our differentiated next-generation PD-1 inhibitor, which serves as a revenue generator when it comes to nasopharyngeal cancer and as a revenue multiplier when combined with novel molecules from our pipeline, like Casdozokitug, which we're studying in liver cancer, and Tagmokitug, which we're studying across a range of cancer indications, among them gastrointestinal, head and neck and, most recently, prostate cancer. Our execution rests on a tightly integrated financial, commercial and development strategy that captures LOQTORZI's maximum potential along both of those dimensions while advancing the pipeline in an efficient manner. NPC alone is big enough to cover the core cash burn at a projected $175 million a year at peak share, and that figure excludes clinical trial costs, which we look at separately. Pairing LOQTORZI with pipeline assets in proprietary combinations amounts to a 2-for-1 win, with label expansion for LOQTORZI included upon any approval. Naturally, that also brings commercial synergies. This is how, through our current efforts, we can go after $33 billion in market opportunity. The third leg of the strategic Triad is Treg depletion with Tagmokitug across cancers and across nonproprietary combinations, which we regard as a foundational Treg depletion platform rather than simply another checkpoint adjunct. Beyond that, we want to investigate Treg depletion as a possible new scaffold across cancer therapies. Tregs broadly mediate immune response, and cancer hijacks immune mediation in order to grow and proliferate. A great many cancer therapies either result in or are limited by Tregs glingeri. So our strategic objective is to broadly deploy Tagmokitug across cancers and nonproprietary therapies. During the last quarter, we closed the first such arrangement with J&J in prostate with a T-cell engager. Right now we're looking into other partnering opportunities, encompassing not only T cell engagers but also ADCs, radiotherapy and various bispecifics. As we've said consistently across all of our presentations for a while now, CCR8-based Treg depletion could prove challenging for many reasons. You need the right molecule and the right target. The right molecule means a number of things spanning selectivity, affinity, pharmacology and everything else. And the right target means immune context along with the nuances of the biology. More recently, it has become clear that, the therapeutic promise of Treg depletion notwithstanding, some market participants are pausing or stopping their programs, while others are accelerating and expanding theirs. Understanding the nuances at play is essential for all of us. So I've asked my Chief Scientific Officer, Theresa Lavallee, to take a few minutes with you today and offer a lens through which to view how the field is evolving. I hope you find it useful. Additionally on today's call, Rosh Dias, who serves as our Chief Medical Officer, is going to bring everyone up to speed regarding the trials, how enrollment is going, and the timing of results. Sameer Goregaoker is going to walk through the Q1 revenues and also give everyone an update on how we're executing commercially. Our projection remains that we will reach roughly $15 million per quarter at some point during this year, 2026, and $30 million to $35 million per quarter at some point in 2027, along with a peak market share of approximately $44 million per quarter at some point in 2028, which works out to around $175 million a year. Following Sameer, Brian McMichael will take you through our financials. With that said, I'll now hand the call over to Rosh. Dr. Dias?

Rosh Dias executive
#3

Thanks, Denny, and good afternoon to all of you. Through the first quarter, we kept moving forward with our tightly focused clinical development program for the molecules in our pipeline, including Tagmokitug, and we feel good about where things stand with both molecules — enrollment is going nicely and we are on schedule. Not long ago, we shared that target accrual has been reached in our <<inaudible>> randomized trial in first-line hepatocellular carcinoma. To jog your memory: this is a study of 72 patients across 3 arms, evaluating 2 active doses of Casdozokitug together with toripalimab and bevacizumab against torizev by itself, and it's built to better define the efficacy and safety of this triplet while also tackling the FDA's Project Optimus and the contribution of components; the study rests on earlier data we showed last year at ASCO GI, in which casdozo added to the current standard of care, atezo and bev, produced an overall response rate of 38% and a highly encouraging complete response rate of 17%, and both of those beat the historical figures for atezo and bev alone, which were 30% and 7.7%, respectively. Enrollment has gone smoothly, and we expect to have initial data in hand around the midyear time frame, in line with projections. Based on what the prior casdozo-HCT trial showed us, we anticipate the response data will mature over time afterward, possibly quarter-to-quarter. Now on to Tagmokitug, our CCR8 cytolytic antibody. At present we are conducting 2 active protocols within a targeted clinical program in tumor types where CCR8 intratumoral expression levels and the activity previously demonstrated in the CCR8 field justify further study. The first protocol broadens our approach in head and neck squamous cell carcinoma and is based on the late-line head and neck squamous cell data we presented at AACR 2025, where we showed tumor immune cell remodeling toward a more cytotoxic state with monotherapy, plus a partial response in the fourth-line patient receiving the tagmo-tori combination. Our ongoing 40-patient expansion examines 2 active doses of tagmo combined with tori, specifically in a second-line population. Enrollment has moved along well, and we expect to have data for 40 patients with a varying number of scans around the midyear frame. Our second protocol examines multiple cohorts under an umbrella protocol, as we've discussed before. Cohort A studies the tagmo-tori combination in 40 patients with second-line upper GI adenocarcinoma, which covers gastric adeno, gastroesophageal junction adeno and esophageal adenocarcinoma, at 2 dose levels of tagno combined with tori. This cohort is up and running and continues to enroll well. We expect initial data to be available midyear, as projected. Cohorts B, C and D are all active and accruing, and we remain on track to show initial data through the second half of this year, as previously communicated. Cohorts B and C of this protocol focus on esophageal squamous cell carcinoma, where tori's activity regardless of PD-L1 status is especially pronounced and serves as the foundation for tori's approval in Europe as the only PD-1 approved across all PD-L1 levels in this tumor type. We are looking into the tagmo-tori pairing for second-line ESCC, and for first-line ESCC, we're studying tagmo plus tori alongside chemotherapy as a safety cohort. In cohort D, the focus is tagmo and tori for fourth-line plus microsatellite stable colorectal carcinoma without liver mets — a condition showing rising incidence, especially among younger age groups, and one with a significant unmet medical need, since the current standard of care offers very limited benefit. Finally, we've achieved great progress on the J&J Tagmokitug T-cell engager combination cohort in prostate cancer, which will be the first under a new multi-cohort protocol — an approach letting us efficiently add further Tagma combination cohorts with other novel mechanisms under one protocol. We still expect the first patient this fall. With that, I'll pass it to Theresa. Theresa?

Theresa Lavallee executive
#4

Thanks, Rosh, and good afternoon, everyone. There are three subjects I want to address today. I'll begin with two aspects regarding Tagmokitug, since the CCR8 competitive landscape keeps shifting, and I'll give a brief overview of why pharmacology and drug development matter. After that, I'll walk through the Tagmokitug pharmacology data we've generated so far. Those findings have underpinned the chance to broaden Tagmokitug's development through J&J T-cell engager, a first-of-its-kind pairing with CCR8 depleting antibodies and a potentially complementary anticancer therapy. It's our first nonproprietary combination to move into clinical development, and we're thrilled about it. So let me begin by going over a few of our analysis plans for the randomized CATALYST-202 study of Casdozokitug. Now that the Casdozokitug HCC study has full enrollment, we're able to conduct the biomarker analysis. For data readouts, we've placed priority on two things: biomarkers tied to response, and pharmacodynamic biomarkers that help establish contribution of effect for Casdozokitug. The earlier Casdozokitug-HCC study gave us a modest data set hinting that greater IL-27 expression within tumors correlated with response. That said, we only had 7 tumor samples, representing just 25% of evaluable patients. Even so, the analysis revealed that tumors from the 4 patients who responded carried a higher level of IL-27 protein than the 3 patients with progressive disease. In the ongoing CATALYST-202 study, we have pretreatment tumor samples available for nearly every patient and anticipate having IL-27 expression data at the time we read out the study. We also intend to run circulating tumor DNA analysis. Circulating tumor DNA is increasingly recognized as a valuable biomarker for assessing tumor burden and treatment response. When tumor cells grow, they release DNA into the patient's bloodstream. And numerous studies demonstrate that a drop in circulating tumor DNA levels after treatment is linked to improved survival outcomes. Circulating tumor DNA is already used as a marker for minimal residual disease in hematological malignancies, and the field is putting substantial effort toward achieving the same for solid tumors. Because responses in HCC tend to be delayed, we're keen to investigate this as an earlier surrogate marker for efficacy. Now let me turn to tagmokitug, our cytolytic CCR8 antibody, which we're studying across multiple indications. With the competitive landscape shifting — some teams pausing or halting their programs while others push theirs into late-stage development — these differing results might come down to the fundamentals of drug development. Early phase clinical studies need to answer two questions: right drug, right target. Getting the right drug demands four essential pharmacological elements: good PK and potency, demonstrating you can deliver the drug at the necessary exposure; and third, dose-dependent effects on the intended target, demonstrating the drug has engaged the target and influenced it in a dose-related way. And fourth, a safety profile that's acceptable both alone and in combination. Most CCR8 antibodies pursue a bind and kill MOA in order to deplete intratumoral Tregs. But as we've said repeatedly, the CCR8 receptor is a GPCR. Everyone knows that generating antibodies that are both potent and selective against GPCRs is a difficult task. That point is being driven home once again by the CCR8 category. Back in April, during the AACR conference, Amgen and Gilead both gave presentations about their CCR8 pipelines. What the results reveal is a mixed picture, and the toxicity profile associated with these antibodies isn't something that appears in certain other CCR8 efforts. After sharing data that showed just 2 responses among 77 patients who received treatment, Amgen stopped enrolling people in its program. Roughly one-third of those patients got AMZ355 together with pembrolizumab. Out of the 12 individuals with gastric cancer, a single partial response was seen. Those findings stand in sharp contrast to the gastric cancer results coming from what is now Sino Biopharma, where LM-108 paired with PD-1 inhibitors produced a 36% overall response rate. Gilead, by comparison, did demonstrate antitumor activity, which included single-agent activity in tumor types recognized for having a large proportion of CCR8-positive Tregs. Gilead is currently moving its asset into Phase II development across multiple studies, and we are waiting for further data sets. To sum up, it appears that a lot of the CCR8 programs being discontinued are being dropped because their drug-like properties come up short and they fail to satisfy the right drug criteria. By contrast, Tagmokitug has demonstrated solid pharmacology and has satisfied every requirement for right drug, with excellent linear dose and dose-dependent PK, potency in both binding and killing the target, dose-dependent immune effects and a safety profile that is acceptable, whether or not toripalimab is included. Now that the right drug is being investigated, our focus has shifted toward resolving the question of hitting the right target. As you've observed, we are pursuing data aggressively to back the right combination for optimal efficacy across cancers, lines of therapy and immune context. We are assessing Tagmokitug alongside either toripalimab, a PD-1 inhibitor, or pritamig, a T cell engager; we intend to assess tagmokitug in additional combinations where Tregs are linked to therapy resistance, for example ADCs or radiotherapy. Our belief is that this will guide our development broadly across anticancer therapies regarding the optimal approach to overcoming Treg-driven resistance in cancer patients. Having said that, I'll hand the call over to our Chief Commercial Officer. Sameer?

Sameer Goregaoker executive
#5

Theresa, thanks, and good afternoon to all of you. Let me give you some perspective today on what we delivered in Q1, the demand signals we're seeing, and where we're concentrating going forward to generate growth. During Q1 2026, LOQTORZI net sales rose 61% compared with Q1 2025. Looking sequentially, net sales came in at $11.8 million, down from $12.4 million in Q4 '25. That outcome matched the usual seasonal pattern we see in a first quarter, though this year it was also affected by harsh weather in many regions of the country, something others have observed as well. To get a clearer read on the seasonal effect this year, we looked at a basket of 85 oncology products. Across the past 4 years, we found those products declined by an average of 5% from Q4 to Q1. In 2026, though, that basket saw a sharper drop of 10%, probably because of the severe winter storms that struck most of the country. Now that this seasonal pressure is behind us, we anticipate LOQTORZI revenue growth will accelerate through the rest of 2026, based on a deeper look at the drivers behind our growth. We're happy to share that LOQTORZI new starts hit their highest level ever in Q1. Two things drove that: first, wider prescribing across new accounts; and second, deeper use via repeat ordering within accounts we already have. All told, breadth and depth of ordering accounts grew 21%, and treatment duration keeps rising quarter-over-quarter. Going forward, we have 2 clear levers to sustain demand growth. First, we're targeting a reduction in chemo-only use, especially in the community setting, by continuing education around NCCN guidelines and our Phase III data, which includes the 6-year long-term survival benefit analysis. Second, we're aiming to reduce off-label PD-1 use in NPC, which stems largely from misperceptions about guidelines and indications. On both fronts, these efforts strengthen LOQTORZI's standing as the sole approved and available immune therapy in NPC, delivering a superior survival benefit compared with chemotherapy alone. We're advancing this plan, deploying targeted investments to sharpen our execution. Notably, new claims data purchases have widened our visibility into chemo-only and off-label IOUs across as much as 70% of addressable patients. That broader visibility is now feeding into patient alerts, allowing earlier, more precise field targeting and multichannel execution. Our inside sales team is fully up and running, substantially extending our reach into the community setting, which is a key growth driver. We're also expanding digital education via KOL video programs, targeted EMR initiatives, and pilots on emerging HCC AI platforms. These AI platforms are growing quickly — oncologists are adopting them rapidly, and they're increasingly informing treatment decisions. On guidance, we still expect 10% to 15% demand growth per quarter on average across the 2026 quarters. Our emphasis remains on fostering broader and deeper adoption throughout community and academic settings, backed by lengthening treatment duration. With that, I'll hand the call over to Brian McMichael, our Chief Financial Officer.

Bryan McMichael executive
#6

Thanks, Sameer, and hello everyone this afternoon. I'd like to begin by covering some important updates on the financial and operational side, and after that I'll walk you through where the company stood financially when the quarter closed, along with our results for Q1 2026. The standout financial development during this quarter was the follow-on equity offering that we brought up during our previous earnings call. To bring you up to speed, net proceeds came to $54 million in total, and that figure reflects the underwriters' overallotment option being exercised in full. With these proceeds, our liquidity has been made stronger, and the money is backing the new Tagmokitug and prostate studies, larger investments in LOQTORZI capabilities aimed at hitting revenue targets more quickly, and general corporate purposes. On the sales side, beyond the detail on LOQTORZI net revenues that Samir shared, I'd like to note that our plan is to give full year 2026 revenue guidance during the August earnings call, just as we said on the prior call. Now let me move to operating expenses. For Q1 2026, R&D expenses from continuing operations came in at $21.5 million, which is lower than the $24.4 million recorded in the first quarter a year earlier. That drop was mainly driven by savings from having fewer people on staff and lower infrastructure costs, which shows our tight spending discipline, and it was partly offset by more money going into the pipeline. SG&A expenses from continuing operations reached $23.1 million in the first quarter, compared with $26 million in Q1 2025. This reduction shows the ongoing savings that followed Coherus' complete exit from the biosimilar business, which, as we discussed with you today, wrapped up over 1 year ago; let me now shift to the balance sheet. At the close of the quarter, total cash, cash equivalents and investments stood at $167 million, a slight decline from $172.1 million at year-end. With the recent raise factored into our financial plans, we feel we have enough funding to carry us through key data readouts in 2026 and 2027; with that said, I'll give the call back to Denny.

Dennis Lanfear executive
#7

Thank you, Bryan. Operator, we're ready to go to the questions.

Jay Olson analyst
#8

Regarding LOQTORZI, could you explain what’s behind the trend in how long existing patients stay on treatment on average, which keeps increasing? Are first-line patients the reason that duration is extending? Also, congratulations on the new patient starts during the first quarter. Could you provide some detail on the breakdown of those patients between first line and second line? And at some point, what percentage of LOQTORZI patients should we expect to be in the first-line setting? Then, if I may, I have a follow-up about tagmo.

Dennis Lanfear executive
#9

Thanks, Jay. I’ll have Sameer go through that for you. Sameer, would you like to take Jay’s question on treatment duration and the rest?

Sameer Goregaoker executive
#10

Appreciate that, Jay. Thanks for asking. There were a few parts to what you raised. So let me just confirm I understood you right. Your first question concerned how long patients typically stay on treatment on average, and how that breaks down between those who are new and those who are already patients. Did I get that right, Jay?

Jay Olson analyst
#11

Yes; and then — yes.

Sameer Goregaoker executive
#12

Yes; as far as how long treatment lasts, what I'm able to share is that it varies according to which group of patients we're talking about; there are 2 groups. The first group consists of first-line locally advanced and first-line metastatic patients. The second group is made up of monotherapy patients, meaning the later-line metastatic patients. In the clinical trials in the real world, for the first-line patients we are observing a longer duration of therapy than for the second-line monotherapy patients; regarding new and existing patients, I think the same dynamic is at work for both the new and existing patients. So overall, we're observing that the duration keeps increasing the further away we get from launch and eventually, hopefully, we'll get close to the clinical trial duration; and the next question concerned new patient starts in first line and second line; so right now, we're seeing roughly 75% to 80% of our patients arrive from the metastatic setting, both the frontline metastatic setting and the second-line metastatic setting and a smaller percent of patients arrive from the locally advanced recurrent setting. And that matches physicians initially at launch, placing patients in the later line patients and then shifting the use of therapy to an earlier line setting. The further into the launch we get, we would expect that we get more locally advanced recurrent patients. And the last thing I'll say is we also now have visibility into where these patients are located. We've purchased a lot of claims data. So we know which physicians are managing these locally advanced recurrent patients, and we're going after those accounts and physicians to educate them on LOQTORZI.

Jay Olson analyst
#13

That was really useful and very thorough. I appreciate you walking through it in such detail. Regarding tagmo, since the readout for second-line head and neck and gastric cancer should come around the middle of the year, could you explain what investors ought to take away from those two updates? And are you going to share what comes next in clinical development for both of those programs?

Dennis Lanfear executive
#14

Rosh, would you like to handle the question about the data? After that, Theresa, you can address the next steps.

Rosh Dias executive
#15

Absolutely, and thanks for raising that, Jay. Regarding the data we'll be sharing, we're expecting the first results for second-line head and neck as well as second-line upper GI adeno to come out near the middle of the year. There are a few points I want to make. To begin with, we expect that at minimum half of the patients will be included in the report. When you consider the data and the timing, two main factors likely come into play, correct? The first is how many patients there are. The second is how many scans might be required to demonstrate activity. So, on the patient count again, my expectation is that we'll have 50% or more of patients. As for the scan numbers, there's a bit more fluctuation there. We'll be evaluating overall response rate. We'll be evaluating clinical benefit rate. We'll be evaluating safety, though it will take somewhat longer for duration to truly mature. And as you're aware, the genuine advantage of IO has come from lengthening that tail. So I'd keep an eye on those key metrics initially.

Theresa Lavallee executive
#16

And to build on what was just said, Jay, thank you, since we are really thrilled when we consider what comes next. So when we examine the results, especially regarding durability — well, ORR is good. That means 30% or more reduction in tumor size, but what counts is durability, given that survival serves as the regulatory endpoint. So we're considering whether there is enough efficacy to back favorable regulatory approaches, and every one of these trials is set up, should the signal appear, to enroll enough patients for that. Beyond that, whether there's a patient group or some method of enriching patients is another result we're closely examining, to understand the immune context. And then, is there a path to move forward into a trial aimed more toward later-stage development? So from these studies, as data come out, we will be seeking both of those results and directions.

Paul Jeng analyst
#17

Turning to tagmo, I have one more thing to ask regarding the head and neck cancer data you'll be reporting, mainly about patient demographics. Could you address what share of patients you'd anticipate being PD-1 experienced? Also, is there a plan to separate out responses according to HCV status? And then, how do you think about the...

Dennis Lanfear executive
#18

Yes. Paul, Paul, let's pause right there and just take one question. Let's handle that one, and then we can continue afterward. Theresa, Rosh, would either of you like to field that?

Rosh Dias executive
#19

Sure, I'm able to address that one. Thanks for asking, Paul. To confirm, every patient involved in the second-line head and neck trial is going to have prior exposure to PD-1 or PD-L1; and indeed, HCC status counts as one of the main stratification factors.

Analyst analyst
#20

I did. Yeah. So my question is really around what your expectations are for the response rate hurdle, given the data that some investigational EGFRs and even ADCs have generated in this setting.

Rosh Dias executive
#21

Yes, I can address that one too. So to begin with, when it comes to the overall response rate, today's standard of care is quite poor. That standard is cetuximab, and the ORR with it usually falls somewhere between 13% and 15%. You're entirely correct; the landscape is indeed shifting and developing thanks to the EGFRs. There are a couple of things I'd like to note. First, we have favorable results both in the first-line and in the second-line setting, which in my view makes these agents better suited to the first-line setting. Second, I believe most of the advantage is actually attributable to HPV negative status. That, I think, means the HPV positive patients — who make up approximately 40% of subjects in total — remain fairly wide open. So that's essentially how we view today's benchmarks and the data sets as they evolve.

Dennis Lanfear executive
#22

Theresa, do you have anything to add?

Theresa Lavallee executive
#23

Yes, I do. Obviously, we're keeping a close eye on this, especially given the announcements around the Nectin ADC data — that's really exciting, and it points to a fast development path in head and neck. The data that's emerging clearly demonstrates a non-EGFR strategy in the frontline setting, which indicates there's both room and appetite for novel agents. What stands out to us about this mechanism is that our initial output involves PD-1 and tagmo. And regarding your question, the first study is simply asking whether we can rescue PD-1 resistance, given that all of these patients are PD-1 failures. Expanding into combinations with any and all of these agents could make a great deal of sense. So beyond streamlining our development through a way to push forward the later stage, we also identify opportunities to broaden and enhance the durability of many of these responses, particularly when it comes to ADCs as we pursue combinations.

Brian Cheng analyst
#24

To start, regarding LOQTORZI — could you share additional detail on how the weather affected the top line? Is it that patients cannot receive a further cycle of LOQTORZI? Or does weather create an access problem? Beyond that, how should we square that situation with the record new patient starts reported for this quarter? We also have a follow-up.

Dennis Lanfear executive
#25

All right. Thank you, Brian. Sameer, would you like to handle that?

Sameer Goregaoker executive
#26

Absolutely, and thanks for raising that, Brian. We're in year three since launch now, which means our understanding of seasonal trends is getting sharper. A degree of seasonality showed up in the prior year, though back then it was somewhat premature to draw conclusions. This time around, the seasonal effect appeared once more. That prompted us to look more closely at what is actually going on within the oncology space, so we assembled a group of 85 oncology molecules. What stood out was quite compelling: across the past 4 years, that group displayed an extremely steady 5% drop between Q4 and Q1. What caught us off guard was a bigger drop in 2026, when that same group fell 10% from Q4 to Q1. So the pattern is roughly what we anticipated — Q1 tends to bring a fairly steady downturn, after which the majority of products return to growth in Q2. It appears we're tracking a comparable trajectory, correct? With that said, when it comes to bridging new patients and existing patients, our read is that roughly 2 significant winter storms hit us, and they disrupted somewhere between 2 and 3 weeks during Q1; my sense is that many patients following either 3-week or 2-week cycles ended up skipping their cycles. Consequently, for a substantial share of patients, that whole cycle was lost, and their cycle clock got reset. So a chunk of patients each lost those individual cycles. None of that relates to new patient starts, correct? New patients matter enormously because they fuel our growth down the road. We're quite encouraged that new patient growth came in strong, and those individuals will turn into existing patients in quarters ahead. Those are the 2 forces at work.

Dennis Lanfear executive
#27

Another thing I want to mention, Brian: comparing Q4 to Q1 of last year, I believe the decline was roughly 3%. This year, I think it comes to something like 5%. So when you factor in the storms, that's essentially consistent; yet when you also factor in the starts, my view is that we ought to get right back onto the growth curve this very quarter. Brian, did you have a follow-up question?

Brian Cheng analyst
#28

Yeah, we do. Perhaps regarding the 202 study, Theresa, you mentioned the significance of circulating tumor DNA as well as IL-27 expression in the forthcoming data when it comes to determining how those expressions relate to tumor reduction. Based on the preclinical model, do you have any idea how closely they track each other when it comes to how much IL-27 goes down relative to tumor reduction in that preclinical model?

Dennis Lanfear executive
#29

Thanks, Brian.

Theresa Lavallee executive
#30

Right. The preclinical models aren't giving us a clear signal in that setting. What we've observed with mice is a strong tissue-specific effect. For it to show up, the tumors need to be located in either the lung or the liver; and because of how much IL-27 is expressed in those sites, that signal does come through. And there are 2 things we're genuinely focused on — I think this just helps frame expectations for the midyear readout, and we've discussed it on several occasions — namely that this is an initial readout. In CATALYST-201, the earlier atezo-bev trial, the first readout showed an overall response rate of just 27%. Yet many patients remained on study, and we observed tumor shrinkage that kept deepening. That's why we believe the initial readout, with trends in circulating tumor DNA plus an examination of whether outcomes differ according to IL-27 levels, will truly provide a glimpse into how likely it is that the study turns out positive as the data mature.

Nick Quartapella analyst
#31

Nick Quartapella here, filling in for Colleen. One quick item regarding the program: when comparing atezo-bev with tori-bev as the combination backbone, should we anticipate any variation in how well each works or in their safety profiles?

Rosh Dias executive
#32

Yes, and thank you, Nick, for raising that. As I believe you remember, we discussed the trial involving toripalimab plus bev against sorafenib. What that trial demonstrated was overall survival that was quite comparable to atezo-bev — perhaps even a bit better — though clearly this wasn't a head-to-head comparison. That gives us a degree of confidence, I'd say. Additionally, the ADA rate associated with atezo is generally much greater than what we see with toripalimab. Those 2 factors, taken together, leave us feeling fairly confident that tori-bev serves as a solid backbone to build upon.

Theresa Lavallee executive
#33

The safety profile has looked pretty favorable, honestly. In fact, that stands out as one of the highlights, especially for this disease, in the frontline HCC setting; and really, across all of them, it hasn't introduced any extra or novel toxicities to any regimen, whether that's atezo, tori, or pembro that's been studied so far.

Mike Nedelcovych analyst
#34

There are two things I'd like to ask. My first one concerns Tagmokitug. Theresa, you touched on this during your comments, yet as I understand it, Lenovo has kicked off a Phase III study for its CCR antibody. Could you expand a little on what you said earlier? From two angles, how significant is this move — first for confirming the mechanism, and second for what it tells us about the competitive picture? And if you're able to address particular overlaps or distinctions involving their molecule and their strategy versus Tagmokitug, that would be extremely useful.

Dennis Lanfear executive
#35

Appreciate that, Mike. Theresa?

Theresa Lavallee executive
#36

Absolutely, that's a great question, and it matters a lot, since we're watching some programs move forward while others get halted. Sino Biopharma, working with LM-108 — or filled keybart — has launched 2 Phase III trials. As a matter of fact, just last week they reported dosing the first patient in their gastric cancer Phase III, and they've also got an MSI-high CRC study running as a pivotal trial. So their confidence is clear, and they're doubling down on both this program and the molecule, plus they'll be presenting at ESMO this year. On top of that, we're seeing companies such as Gilead kick off 2 randomized Phase II studies — one in gastric cancer, one in colorectal — while AbbVie pushes ahead in colorectal cancer and BMS keeps adding patients to their trial. So we believe what separates these efforts from the ones being parked, or from the negative data, or from the absence of activity that Amgen attributed to pharmacology, is exactly this momentum. That's why we're incredibly enthusiastic about watching these programs progress and about how our molecule's properties make it thrilling to now anticipate the data readouts later this year.

Dennis Lanfear executive
#37

Mike, did you have a follow-on question for us?

Mike Nedelcovych analyst
#38

If it's all right, I'd like to ask one more about LOQTORZI. Sure. I'm just wondering — now that your understanding of seasonality has improved, do you still believe LOQTORZI will reach roughly $30 million to $35 million in quarterly sales during 2027? Or could that take somewhat longer?

Dennis Lanfear executive
#39

We're confident we can. During my prepared remarks, I restated guidance on 3 key matters regarding revenues. The first is hitting $15 million per quarter at some point in '26. The second is hitting $30 million to $35 million per quarter at some point in '27 — and the third is hitting an annualized $175 million per year, which works out to about $44 million a quarter at some point in 2028; and I believe the data purchases we've made and what we now know about the therapeutic area give us confidence that we'll be able to achieve this.

Douglas Tsao analyst
#40

I apologize—are you able to pick me up?

Dennis Lanfear executive
#41

Are you able to pick me up...

Douglas Tsao analyst
#42

My apologies for that — I had muted you. So perhaps regarding the LOQTORZI matter and how it bears on storms, did this mostly hit patients who were just beginning treatment? Or did it come down to those already in the midst of therapy? And ought we to view it as merely revenue pushed back that ought to be recovered later in the year?

Dennis Lanfear executive
#43

Sameer, would you like to field that one to start?

Sameer Goregaoker executive
#44

I'll give that a try. Doug, thanks for raising it. Now, regarding the opening portion of what you asked — yes, I'd say the impact landed on patients we already had. When it comes to people who are new to us, like I said during my prepared comments, the number of fresh accounts that began or resumed treatment with new patients came in higher than what we'd seen previously. So growth among new patients looks strong to me. My read is that what occurred with the existing patient group stems from seasonality, shifts in insurance, and the weather as well — a few disruptions hit treatments already underway, and that's where we shed some cycles. I doubt we recover those cycles, since when you're on a 3-week cycle and you skip it during the current week, you're essentially starting over inside a fresh 3-week cycle, meaning that single cycle is gone for good, more or less. That said, let me return to the point we made before, okay? That covers Q1, correct? So we feel quite optimistic about new patient starts staying on track, along with our capacity to generate demand growth through the remainder of this year.

Douglas Tsao analyst
#45

Can I jump to a follow-up, Denny?

Dennis Lanfear executive
#46

Sure.

Douglas Tsao analyst
#47

So perhaps just on — clearly, we've got a considerable amount of readouts starting in the middle portion of this year and going into the back half. I suppose when you consider your situation regarding the balance sheet, Denny, can you — and I believe you'd definitely aim to win, or operate on the assumption that these studies will succeed. Do you feel you're positioned to keep pursuing all of these opportunities? Or might some prioritization be required?

Dennis Lanfear executive
#48

I'd point you to what I said in my prepared remarks at the start of this call. Yet we're definitely financed through '26 and all of '27 as every data card turns over. One practice of ours is that when a clinical trial lacks funding, or we have something we consider valuable, we bring it to our investors; and right now, every one of our clinical trials has funding. We recently raised money, as you're aware, and that truly resolved the matter of the CRC study, which hadn't been funded, plus the prostate study with J&J, and I think you'd agree both are extremely valuable. So that's essentially how we handle it; at this moment we don't anticipate any further trials. I believe we've performed very well with an extremely broad development program spanning and a quite tightly focused program concerning. So I think we're ready.

Dennis Lanfear executive
#49

Appreciate that, Heidi, and thanks to everyone for being here on today's Q1 2026 call. We're excited to connect with you once more on our August call, which should be a lot of fun. Between now and then, you'll find us presenting at Jefferies, and we'll be at ASCO as well. Thanks so much. Take care.

Operator operator
#50

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Coherus Oncology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Coherus Oncology, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.